193 related articles for article (PubMed ID: 10707792)
21. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in the treatment of refractory follicular lymphoma -- six doses are better than four.
Avilés A; León MI; Díaz-Maqueo JC; García EL; Cleto S; Neri N
J Hematother Stem Cell Res; 2001 Apr; 10(2):313-6. PubMed ID: 11359679
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.
Inwards DJ; Fishkin PA; Hillman DW; Brown DW; Ansell SM; Kurtin PJ; Fonseca R; Morton RF; Veeder MH; Witzig TE
Cancer; 2008 Jul; 113(1):108-16. PubMed ID: 18470909
[TBL] [Abstract][Full Text] [Related]
25. Is rituximab effective as a single agent in mantle-cell lymphoma?
Grillo-López AJ
Nat Clin Pract Oncol; 2005 Oct; 2(10):500-1. PubMed ID: 16205768
[No Abstract] [Full Text] [Related]
26. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
27. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen.
Sachanas S; Pangalis GA; Vassilakopoulos TP; Korkolopoulou P; Kontopidou FN; Athanasoulia M; Yiakoumis X; Kalpadakis C; Georgiou G; Masouridis S; Moschogiannis M; Tsirkinidis P; Pappis V; Kokoris SI; Siakantaris MP; Panayiotidis P; Angelopoulou MK
Leuk Lymphoma; 2011 Mar; 52(3):387-93. PubMed ID: 21133713
[TBL] [Abstract][Full Text] [Related]
28. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response.
Crysandt M; Neumann B; Das M; Engelbertz V; Bendel M; Galm O; Osieka R; Jost E
Eur J Haematol; 2007 Dec; 79(6):546-9. PubMed ID: 17903214
[TBL] [Abstract][Full Text] [Related]
31. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
32. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.
Spurgeon SE; Pindyck T; Okada C; Chen Y; Chen Z; Mater E; Abbi K; Epner EM
Leuk Lymphoma; 2011 Aug; 52(8):1488-94. PubMed ID: 21623691
[TBL] [Abstract][Full Text] [Related]
33. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
Berinstein NL; Mangel J
Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
[TBL] [Abstract][Full Text] [Related]
34. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.
Maeda T; Yamada Y; Tawara M; Yamasaki R; Yakata Y; Tsutsumi C; Onimaru Y; Kamihira S; Tomonaga M
Int J Hematol; 2001 Jul; 74(1):70-5. PubMed ID: 11530808
[TBL] [Abstract][Full Text] [Related]
36. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
37. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
38. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
39. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Barbiero S; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Renna F; Lobetti Bodoni C; Gueli A; Passera R; Musto P; Boccadoro M; Tarella C; Ladetto M
Ann Hematol; 2013 Nov; 92(11):1503-11. PubMed ID: 23737092
[TBL] [Abstract][Full Text] [Related]
40. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
